TY - JOUR ID - 46238 TI - Serum Levels of IL-22 in Patients with Oral Lichen Planus and Cutaneous Lichen Planus JO - Journal of Dentistry JA - DENTJODS LA - en SN - 2345-6485 AU - Mardani, Maryam AU - Torabi Ardakani, Shiva AU - Dastgheib, Ladan AU - Hamidizadeh, Nasrin AD - Oral and Dental Disease Research Center, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran. AD - Dept. of Pathology, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran. AD - Molecular Dermatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Y1 - 2020 PY - 2020 VL - 21 IS - 4 SP - 330 EP - 334 KW - IL-22 KW - Oral lichen planus KW - Cutaneous lichen planus KW - serum DO - 10.30476/dentjods.2020.84667.1096 N2 - Statement of the Problem: Lichen planus disease is a chronic inflammatory disorder of mucosal and cutaneous tissues, which its etiology and pathogenesis are unclear. Cytokines play an important role in the initiation, maintenance of inflammatory and intercellular cross-talk. Purpose: We assessed serum levels of IL-22 in patients with oral and cutaneous lichen planus and made comparison with healthy individuals. Materials and Method: Peripheral blood samples of 40 patients with lichen planus disease, included two groups of oral lichen planus (n=20) and cutaneous lichen planus (n=20) were compared with 32 healthy individuals. Serum samples were prepared from LP patients, using a commercial ELISA Kit, IL-22 concentration was measured in each serum sample. The obtained data were then analyzed using the Kruskal-Wallis one-way analysis of variance. Results: IL-22 serums level was significantly higher in patients with oral lichen planus than the healthy control group (p < 0.001). No statistically significant differences were observed in serum levels of IL-22 in cutaneous lichen planus patients compared to the controls (p = 0.183). Conclusion: Increased IL-22 serum levels in patients with oral lichen planus may play an important role in the pathogenesis of oral Lichen planus. The administration of the recombinant or antagonist of IL-22 could be a new therapeutic opportunity in the treatment of oral lichen planus. UR - https://dentjods.sums.ac.ir/article_46238.html L1 - https://dentjods.sums.ac.ir/article_46238_a1a9ed1ad147ac8fc934a460e022de24.pdf ER -